Neurocrine Biosciences
NBIX
#1570
Rank
HK$103.64 B
Marketcap
HK$1,033
Share price
2.35%
Change (1 day)
19.99%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): HK$4.96 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are HK$2.86 Billion. , an increase over its 2024 earnings that were of HK$4.80 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 HK$4.98 B3.9%
2024 HK$4.80 B96.41%
2023 HK$2.44 B41.13%
2022 HK$1.73 B73.74%
2021 HK$0.99 B-8.82%
2020 HK$1.09 B77.78%
2019 HK$0.61 B49.83%
2018 HK$0.41 B-142.57%
2017 -HK$0.97 Billion-14.73%
2016 -HK$1.14 Billion53.15%
2015 -HK$0.74 Billion46.25%
2014 -HK$0.51 Billion29.66%
2013 -HK$0.39 Billion-3530.8%
2012 HK$11.35 M-95.73%
2011 HK$0.26 B
2009 -HK$0.38 Billion-45.38%
2008 -HK$0.69 Billion-58.87%
2007 -HK$1.67 Billion87.3%
2006 -HK$0.89 Billion351.97%
2005 -HK$0.2 Billion-52.09%
2004 -HK$0.42 Billion-10.98%
2003 -HK$0.47 Billion
2001 -HK$0.35 Billion
1999 -HK$0.16 Billion108.32%
1998 -HK$74.48 Million
1996 HK$22.73 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
HK$79.89 B 1,501.26%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$51.71 B 936.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$201.70 B 3,942.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$0.65 B-86.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$0.33 Billion-106.56%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$0.39 B-92.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$37.59 Million-100.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$12.79 B 156.38%๐Ÿ‡ฌ๐Ÿ‡ง UK